Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Precision Biosciences Inc (DTIL)

Precision Biosciences Inc (DTIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Precision BioSciences: Q4 Earnings Snapshot

Precision BioSciences: Q4 Earnings Snapshot

DTIL : 9.38 (-3.50%)
Precision BioSciences: Q3 Earnings Snapshot

Precision BioSciences: Q3 Earnings Snapshot

DTIL : 9.38 (-3.50%)
Precision BioSciences: Q2 Earnings Snapshot

Precision BioSciences: Q2 Earnings Snapshot

DTIL : 9.38 (-3.50%)
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -4.55% and 33.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DTIL : 9.38 (-3.50%)
PRQR : 1.9400 (-1.02%)
Precision BioSciences: Q1 Earnings Snapshot

Precision BioSciences: Q1 Earnings Snapshot

DTIL : 9.38 (-3.50%)
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on April...

DTIL : 9.38 (-3.50%)
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will...

DTIL : 9.38 (-3.50%)
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an upcoming scientific...

DTIL : 9.38 (-3.50%)
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that a late-breaking...

DTIL : 9.38 (-3.50%)
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has received...

DTIL : 9.38 (-3.50%)

Barchart Exclusives

3 Highest-Yielding (And Safest) Dividend Aristocrats To Buy Today
The highest-yielding dividend aristocrats aren't always the safest stocks to buy. Here's what I did to counteract this. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar